As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff ...

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...

Orchestra BioMed, based in New Hope, successfully raised $111 million in just five days to support the advancement of two of its flagship technologies ...

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.